Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
15 Luglio 2024 - 7:14PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of July 2024
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the
'Company')
Transaction notification
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Emma Walmsley
|
|
b)
|
Position/status
|
Chief Executive Officer
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the
financial
instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 July 2024 on shares held
through the Company's Share Reward Plan
|
|
c)
|
Price(s)
and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.1279
|
26
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the
transaction
|
2024-07-11
|
|
f)
|
Place
of the
transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Diana Conrad
|
|
b)
|
Position/status
|
Chief People Officer
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the
financial
instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 July 2024 on shares held
through the Company's Share Reward Plan
|
|
c)
|
Price(s)
and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.1279
|
5
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the
transaction
|
2024-07-11
|
|
f)
|
Place
of the
transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
James Ford
|
|
b)
|
Position/status
|
SVP and Group General Counsel, Legal and Compliance
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the
financial
instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 July 2024 on shares held
through the Company's Share Reward Plan
|
|
c)
|
Price(s)
and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.1279
|
8
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the
transaction
|
2024-07-11
|
|
f)
|
Place
of the
transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Sally Jackson
|
|
b)
|
Position/status
|
SVP, Global Communications and CEO Office
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the
financial
instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 July 2024 on shares held
through the Company's Share Reward Plan
|
|
c)
|
Price(s)
and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.1279
|
16
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the
transaction
|
2024-07-11
|
|
f)
|
Place
of the
transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Luke Miels
|
|
b)
|
Position/status
|
Chief Commercial Officer
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the
financial
instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 July 2024 on shares held
through the Company's Share Reward Plan
|
|
c)
|
Price(s)
and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.1279
|
2
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the
transaction
|
2024-07-11
|
|
f)
|
Place
of the
transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
David Redfern
|
|
b)
|
Position/status
|
President Corporate Development
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the
financial
instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 July 2024 on shares held
through the Company's Share Reward Plan
|
|
c)
|
Price(s)
and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.1279
|
70
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the
transaction
|
2024-07-11
|
|
f)
|
Place
of the
transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Regis Simard
|
|
b)
|
Position/status
|
President, Global Supply Chain
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the
financial
instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 July 2024 on shares held
through the Company's Share Reward Plan
|
|
c)
|
Price(s)
and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.1279
|
26
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume Price
|
|
|
e)
|
Date
of the
transaction
|
2024-07-11
|
|
f)
|
Place
of the
transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Philip Thomson
|
|
b)
|
Position/status
|
President, Global Affairs
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the
financial
instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 July 2024 on shares held
through the Company's Share Reward Plan
|
|
c)
|
Price(s)
and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.1279
|
45
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the
transaction
|
2024-07-11
|
|
f)
|
Place
of the
transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Deborah Waterhouse
|
|
b)
|
Position/status
|
CEO, ViiV Healthcare and President, Global Health, GSK
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the
financial
instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 July 2024 on shares held
through the Company's Share Reward Plan
|
|
c)
|
Price(s)
and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.1279
|
58
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the
transaction
|
2024-07-11
|
|
f)
|
Place
of the
transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Victoria Whyte
|
|
b)
|
Position/status
|
Company Secretary
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the
financial
instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 July 2024 on shares held
through the Company's Share Reward Plan
|
|
c)
|
Price(s)
and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.1279
|
53
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the
transaction
|
2024-07-11
|
|
f)
|
Place
of the
transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Elizabeth McKee Anderson
|
|
b)
|
Position/status
|
Independent Non-Executive Director
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the
financial
instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
|
|
b)
|
Nature
of the
transaction
|
Acquisition of ADSs following the re-investment of dividends paid
to shareholders on 11 July 2024
|
|
c)
|
Price(s)
and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$39.3371
|
14
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the
transaction
|
2024-07-12
|
|
f)
|
Place
of the
transaction
|
New York Stock Exchange (XNYS)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Charles Bancroft
|
|
b)
|
Position/status
|
Senior Independent Non-Executive Director
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the
financial
instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
|
|
b)
|
Nature
of the
transaction
|
Acquisition of ADSs following the re-investment of dividends paid
to shareholders on 11 July 2024
|
|
c)
|
Price(s)
and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$39.3371
|
84
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the
transaction
|
2024-07-12
|
|
f)
|
Place
of the
transaction
|
New York Stock Exchange (XNYS)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Dr Hal Barron
|
|
b)
|
Position/status
|
Non-Executive Director
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the
financial
instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
|
|
b)
|
Nature
of the
transaction
|
Acquisition of ADSs following the re-investment of dividends paid
to shareholders on 11 July 2024
|
|
c)
|
Price(s)
and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$39.3371
|
16
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the
transaction
|
2024-07-12
|
|
f)
|
Place
of the
transaction
|
New York Stock Exchange (XNYS)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Dr Anne Beal
|
|
b)
|
Position/status
|
Independent Non-Executive Director
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the
financial
instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
|
|
b)
|
Nature
of the
transaction
|
Acquisition of ADSs following the re-investment of dividends paid
to shareholders on 11 July 2024
|
|
c)
|
Price(s)
and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$39.3371
|
12
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the
transaction
|
2024-07-12
|
|
f)
|
Place
of the
transaction
|
New York Stock Exchange (XNYS)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Dr Harry Dietz
|
|
b)
|
Position/status
|
Independent Non-Executive Director
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the
financial
instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
|
|
b)
|
Nature
of the
transaction
|
Acquisition of ADSs following the re-investment of dividends paid
to shareholders on 11 July 2024
|
|
c)
|
Price(s)
and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$39.3371
|
12
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the
transaction
|
2024-07-12
|
|
f)
|
Place
of the
transaction
|
New York Stock Exchange (XNYS)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Dr Jesse Goodman
|
|
b)
|
Position/status
|
Independent Non-Executive Director
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the
financial
instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
|
|
b)
|
Nature
of the
transaction
|
Acquisition of ADSs following the re-investment of dividends paid
to shareholders on 11 July 2024
|
|
c)
|
Price(s)
and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$39.3371
|
12
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the
transaction
|
2024-07-12
|
|
f)
|
Place
of the
transaction
|
New York Stock Exchange (XNYS)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Dr Vishal Sikka
|
|
b)
|
Position/status
|
Independent Non-Executive Director
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the
financial
instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
|
|
b)
|
Nature
of the
transaction
|
Acquisition of ADSs following the re-investment of dividends paid
to shareholders on 11 July 2024
|
|
c)
|
Price(s)
and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$39.3371
|
51
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the
transaction
|
2024-07-12
|
|
f)
|
Place
of the
transaction
|
New York Stock Exchange (XNYS)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Dylan Jackson
|
|
b)
|
Position/status
|
PCA of Ms S Jackson (SVP, Global Communications and CEO
Office)
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the
financial
instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 July 2024.
|
|
c)
|
Price(s)
and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.0760
|
1
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the
transaction
|
2024-07-11
|
|
f)
|
Place
of the
transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Victoria Whyte
|
|
b)
|
Position/status
|
Company Secretary
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the
financial
instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 July 2024.
|
|
c)
|
Price(s)
and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.0760
|
16
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the
transaction
|
2024-07-11
|
|
f)
|
Place
of the
transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Iain Whyte
|
|
b)
|
Position/status
|
PCA of Ms V Whyte (Company Secretary)
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the
financial
instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 July 2024.
|
|
c)
|
Price(s)
and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.0760
|
1115
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the
transaction
|
2024-07-11
|
|
f)
|
Place
of the
transaction
|
London Stock Exchange (XLON)
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: July
15, 2024
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|
Grafico Azioni GSK (NYSE:GSK)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni GSK (NYSE:GSK)
Storico
Da Gen 2024 a Gen 2025
